PTC Therapeutics Inc’s recent filing unveils that its EXEC. VP AND CLO Boulding Mark Elliott unloaded Company’s shares for reported $89081.0 on May 15 ’25. In the deal valued at $46.18 per share,1,929 shares were sold. As a result of this transaction, Boulding Mark Elliott now holds 103,901 shares worth roughly $5.39 million.
Then, Boulding Mark Elliott sold 883 shares, generating $40,636 in total proceeds. Upon selling the shares at $46.02, the EXEC. VP AND CLO now owns 103,901 shares.
Before that, Boulding Mark Elliott bought 883 shares. PTC Therapeutics Inc shares valued at $40,640 were divested by the Officer at a price of $46.02 per share.
BofA Securities upgraded its PTC Therapeutics Inc [PTCT] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who increased its forecast for the stock in early May from “a Sell” to “a Neutral”. BofA Securities also remained covering PTCT and has increased its forecast on March 11, 2025 with a “Neutral” recommendation from previously “an Underperform” rating. Scotiabank started covering the stock on March 07, 2025. It rated PTCT as “a Sector perform”.
Price Performance Review of PTCT
On Monday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock jump 1.19% to $51.87. Over the last five days, the stock has gained 0.35%. PTC Therapeutics Inc shares have risen nearly 14.91% since the year began. Nevertheless, the stocks have risen 37.70% over the past one year. While a 52-week high of $58.38 was reached on 03/17/25, a 52-week low of $28.72 was recorded on 05/06/25.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 50.50, which if violated will result in even more drops to 49.14. On the upside, there is a resistance level at 52.59. A further resistance level may holdings at 53.32.
